Circio Holding (”Circio” or ”the Company”) announced, on the 18th of March 2026, that one of the Company’s submitted abstracts has been selected for an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) annual meeting, to be held in Boston, 11–15 May 2026. ASGCT represents the largest and most prestigious gene and cell therapy conference globally, where only a small fraction of submitted abstracts are selected for oral presentations, while also serving as a key venue where companies and potential partners convene to explore licensing and collaborative R&D opportunities.

In summary, Analyst Group views Circio’s selection for an oral presentation at ASGCT 2026 as a qualitatively positive milestone that, when viewed alongside the Company’s recently reported preclinical data, reinforces the growing credibility of the circVec platform. Analyst Group assesses that the combination of a strengthened data package, an upcoming high-profile scientific presentation, and a strong balance sheet positions Circio favorably for deepened partner dialogues and broader industry recognition in the months ahead.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.